ImmunityBio, Inc. (IBRX)
8.08
-0.11
(-1.34%)
USD |
NASDAQ |
Sep 04, 16:00
8.08
0.00 (0.00%)
Pre-Market: 20:00
ImmunityBio Research and Development Expense (Quarterly) : 60.82M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 60.82M |
| March 31, 2026 | 66.89M |
| December 31, 2025 | 63.36M |
| September 30, 2025 | 50.73M |
| June 30, 2025 | 54.74M |
| March 31, 2025 | 47.73M |
| December 31, 2024 | 34.72M |
| September 30, 2024 | 49.94M |
| June 30, 2024 | 50.63M |
| March 31, 2024 | 52.85M |
| December 31, 2023 | 51.03M |
| September 30, 2023 | 47.90M |
| June 30, 2023 | 52.67M |
| March 31, 2023 | 78.76M |
| December 31, 2022 | 52.85M |
| September 30, 2022 | 67.11M |
| June 30, 2022 | 58.64M |
| March 31, 2022 | 51.29M |
| December 31, 2021 | 51.75M |
| September 30, 2021 | 49.28M |
| June 30, 2021 | 53.80M |
| March 31, 2021 | 41.13M |
| December 31, 2020 | 20.26M |
| September 30, 2020 | 17.28M |
| Date | Value |
|---|---|
| June 30, 2020 | 13.71M |
| March 31, 2020 | 13.23M |
| December 31, 2019 | 12.00M |
| September 30, 2019 | 12.05M |
| June 30, 2019 | 13.13M |
| March 31, 2019 | 12.60M |
| December 31, 2018 | 11.88M |
| September 30, 2018 | 13.96M |
| June 30, 2018 | 14.09M |
| March 31, 2018 | 13.39M |
| December 31, 2017 | 11.46M |
| September 30, 2017 | 10.47M |
| June 30, 2017 | 9.106M |
| March 31, 2017 | 8.648M |
| December 31, 2016 | 8.138M |
| September 30, 2016 | 7.964M |
| June 30, 2016 | 5.889M |
| March 31, 2016 | 4.555M |
| December 31, 2015 | 5.106M |
| September 30, 2015 | 3.95M |
| June 30, 2015 | 1.745M |
| March 31, 2015 | 0.603M |
| December 31, 2014 | 0.904M |
| March 31, 2014 | 0.12M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Moderna, Inc. | 588.00M |
| Sarepta Therapeutics, Inc. | 91.26M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |
| Sangamo Therapeutics, Inc. | 26.57M |